A UNSW Sydney-led team of scientists has made an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
By introducing a beneficial natural mutation into blood cells using the gene-editing technique CRISPR, a UNSW Sydney-led team of scientists has been able to switch on production of foetal haemoglobin – an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
People with thalassaemia or sickle cell anaemia have damaged adult haemoglobin – the vital molecule that picks up oxygen in the lungs and transports it around the body – and they require life-long treatment with blood transfusions and medication.
However, people with these diseases who also carry the beneficial natural mutation – known as British-198 – have reduced symptoms, because the mutation switches on the foetal haemoglobin gene that is normally turned off after birth.
The extra foetal haemoglobin in their blood, which has a very strong affinity for oxygen, does the work of the defective adult haemoglobin.
“With CRISPR gene-editing we can now precisely cut and alter single genes within our vast genome,” says study senior author and UNSW molecular biologist Professor Merlin Crossley.
“Our laboratory has shown that introducing the beneficial mutation British-198 into blood cells using this technology substantially boosts their production of foetal haemoglobin.
“Because this mutation already exists in nature and is benign, this ‘organic gene therapy’ approach should be effective and safe to use to treat, and possibly cure serious blood disorders. However, more research is still needed before it can be tested in people,” he says.
The study by scientists from UNSW, the Japanese Red Cross Society and the RIKEN BioResource Centre in Japan, is published in the journal Blood.
The beneficial British-198 mutation, which was first identified in a large British family in 1974, involves a change in just a single letter of the genetic code.
Carriers of this mutation have foetal haemoglobins levels as high as 20% of total haemoglobin, while most people’s foetal haemoglobin levels fall to about 1% of total haemoglobin after birth.
The researchers also discovered how this British-198 mutation works. They found it creates a new binding site for a protein called KLF1 that turns blood genes on.
Mutations affecting adult haemoglobin production are among the most common of all genetic variations, with about 5% of the world’s population carrying a defective gene.
“To turn the new gene editing approach into a therapy for blood disorders, the British-198 mutation would have to be introduced into blood-forming stem cells from the patient,” says Professor Crossley.
“A large number of stem cells would have to be edited in order to repopulate the patients’ blood with genetically enhanced cells.”
The Latest on: Genome therapy
- Codexis inks deal with Takeda to advance gene therapies for rare genetic disorderson March 23, 2020 at 4:45 am
has signed a strategic collaboration and license agreement with Takeda Pharmaceutical (OTCPK:TKPHF) for the research and development of novel gene therapies for certain disease indications, including ...
- Invitae and Muscular Dystrophy Association (MDA) Expand Access to No-Charge Genetic Testing in the U.S. and Canadaon March 23, 2020 at 4:30 am
- Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorderson March 23, 2020 at 4:00 am
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical Company ...
- Association of genetic and epigenetic variants in one-carbon metabolism gene with folate treatment response in hyperhomocysteinaemiaon March 20, 2020 at 10:16 am
Folate supplementation treatment is the first-line therapy in hyperhomocysteinaemia (HHcy). Up to 40% of HHcy patients do not benefit from folate therapy. Genetic and epigenetic factors of one-carbon ...
- COVID-19: the biology of an effective therapyon March 20, 2020 at 10:05 am
So antiviral therapies usually target something unique about the virus—something important enough that a few mutations in the virus won't make the therapy ineffective. Those of you who didn't sleep ...
- Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseaseson March 20, 2020 at 5:29 am
Excessive release of neutrophil extracellular traps (NETs) is associated with disease severity and contributes to tissue injury, followed by severe organ damage. Pharmacological or genetic inhibition ...
- Gene Therapy Market 2020: Worldwide Industry Overview, Supply Demand and Shortage, Trends, Demand, Overview, Forecast 2026on March 19, 2020 at 4:37 am
Gene Therapy Market"2020 report is here in an explicit manner to offer detailed vision about the aspects responsible for enlarging as well as preventing the market growth. The Global Gene Therapy ...
- Avellino Expands Production of Genetic Test Kits for Coronavirus Detectionon March 19, 2020 at 3:24 am
Therefore, a genetic test such as the AvellinoCoV2 test provides clinicians and public health ... About Avellino - Avellino Lab USA, Inc. is a global leader in gene therapy and molecular diagnostics ...
- The ACMG Foundation announces recipient of Carolyn Mills Lovell Genetic Counselor Awardon March 18, 2020 at 5:11 am
She and her genetic counseling colleagues see patients with a wide variety of prenatal and preconception genetics indications in the Johns Hopkins Prenatal Diagnosis and Treatment Center as well as ...
- Biotech pushes blood disorder cell therapy to clinic after $80M roundon March 18, 2020 at 4:01 am
With new financing in its pocket, a Flagship Pioneering-backed cell therapy startup is ready to begin its first in-human tests of a rare disease treatment. Sigilon Therapeutics raised a $80.3 million ...
via Google News and Bing News